MARKET

OGEN

OGEN

Oragenics
AMEX
0.5835
+0.0128
+2.24%
Opening 14:10 05/15 EDT
OPEN
0.5750
PREV CLOSE
0.5707
HIGH
0.6195
LOW
0.5601
VOLUME
42.21K
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
0.5038
MARKET CAP
2.63M
P/E (TTM)
-0.1279
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OGEN last week (0504-0508)?
Weekly Report · 4d ago
Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY
Benzinga · 6d ago
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
Benzinga · 05/07 12:34
Weekly Report: what happened at OGEN last week (0427-0501)?
Weekly Report · 05/04 09:58
Weekly Report: what happened at OGEN last week (0420-0424)?
Weekly Report · 04/27 09:59
Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion
NASDAQ · 04/21 02:41
Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002
TipRanks · 04/20 14:01
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
Benzinga · 04/20 13:04
More
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Webull offers Oragenics Inc stock information, including AMEX: OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.